Replies to post #794 on Idenix Pharmaceuticals (IDIX)

[gofishmarko]

Thanks. The other spinning they've done recently is to say they're most interested in the results from patients who complete the tx. per protocol , or nearly so. It will be interesting to see if they're happy with 70% from that group , as opposed to 70% from the ITT group.

In the real world ( or in the P3 ) they may be right , in the sense that dropouts observed to date in the VRTX trials may not occur as frequently due to better medical management of SEs.